65,437 trials
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Hyperkalemia
Primary: Percentage of Responders — 41.2; 1.0 Percentage of participants — p=<0.001
Coronary Heart Disease
Primary: In-stent Late Loss — 0.29 mm
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Aging · Exercise
Primary: Estimate Cardiovascular Efficiency After Aerobic Exercise — 24.01; 31.2; 32.3 ml/kg(min) — p=.001
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Coronary Heart Disease
Primary: In-stent Late Lumen Loss — 0.19 mm
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) — 5.59; 3.88 Months — p=0.0165
Evaluation of SpO2 Performance
Primary: Accuracy of Oxygen Saturation (SpO2) Measurement by RMS Calculation — 2.1 percent of oxygen saturated hemoglobin
Barlow's Disease · Prolapse; Mitral
Primary: Cardiac Death — 3.9; 3.8 percentage of participants with event
Dental Caries
Primary: Caries Incidence — 137; 123 Participants
Biliary Stricture
Primary: Stent Removability — 132 Participants
Partial Edentulism
Primary: Compare Barrier Membranes by Examining Keratinized Tissue
Lumbar Degenerative Disease · Shared Decision Making · Patient Decision Aids
Primary: The Change of Patients' Control Preference — 1; 1; 16; 14 Participants
Schizophrenia
Primary: Number of Participants With Treatment-related Adverse Events as Assessed